Edition:
India

Athenex Announces Superior Response & Survival With Lower Neuropathy Of A Novel Oral Paclitaxel Versus IV Paclitaxel In Treatment Of Metastatic Breast Cancer


Friday, 13 Dec 2019 

Dec 13 (Reuters) - Athenex Inc ::ATHENEX INC - SUPERIOR RESPONSE & SURVIVAL WITH LOWER NEUROPATHY OF A NOVEL ORAL PACLITAXEL VERSUS IV PACLITAXEL IN TREATMENT OF METASTATIC BREAST CANCER.ATHENEX INC - FIRST ORAL TAXANE TO DEMONSTRATE SUPERIOR RESPONSE RATE & OVERALL SURVIVAL COMPARED TO IV PACLITAXEL IN A PHASE III CLINICAL TRIAL.ATHENEX - ORAL PACLITAXEL & ENCEQUIDAR IS FIRST ORAL TAXANE TO DEMONSTRATE IN A PHASE III STUDY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RESPONSE RATE. 

Company Quote

15.52
 --
21 Jan 2020